UK-based life sciences company Cypralis has secured funding from the Alzheimer’s Drug Discovery Foundation (ADDF) to develop new cyclophilin inhibitors for neurodegenerative diseases.
The $524,000 funding will help augment the existing collaboration, which is facilitated by Johnson & Johnson Innovation, between Cypralis and Janssen Pharmaceuticals to develop the inhibitors.
Go deeper with GlobalData
Cypralis CSO Dr Michael Peel said: "The ADDF funding opens an exciting pathway towards developing a novel class of cyclophilin D inhibitors for neurodegenerative diseases, including Alzheimer’s.
“Many previous publications have recognised the potential for cyclophilin D as a novel target for degenerative disease but no group has published on compounds that combine sub-type selectivity and brain penetration.
“If data from the ADDF funding is encouraging, Cypralis would expect to initiate a lead optimisation campaign in early 2018 with the goal of generating a novel pre-clinical candidate for this extremely challenging and devastating disease."
See Also:
Cyclophilin inhibitors are non-selective between the four commonly screened cyclophilin isoforms known as A, B, C and D.
How well do you really know your competitors?
Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.
Thank you!
Your download email will arrive shortly
Not ready to buy yet? Download a free sample
We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form
By GlobalDataAt present, a joint research programme is being carried out by Cypralis and Janssen to generate a new class of CNS penetrant, selective inhibitors of cyclophilin D to target degenerative diseases, including CNS degeneration.
With the ADDF funding, Cypralis will be able to extend ‘hit-to-lead’ medicinal chemistry and expand its brain-penetrant cyclophilin inhibitors.
In 2013, Cypralis was spun out from Selcia to exploit its expertise in targeting peptidyl-prolyl isomerases involved in many acute and chronic diseases.
